重组酵母乙肝疫苗阻断母婴传播效果观察

The protective efficacy and immunogenicity of recombinant hepatitis B vaccine in prevention of perinatal transmission

应用重组酵母乙肝疫苗对ＨＢｓＡｇ／ＨＢｅＡｇ双阳母亲的新生儿免疫，阻断ＨＢＶ的母婴传播，结果婴儿３、９、１２月龄的保护率分别为８５．５％、９０．０％、９１．８％；抗－ＨＢｓ阳转率分别为８３．０％、９２．０％、９３．８％；ＧＭＴ分别为３７．６ｍＩＵ／ｍｌ、７１．８ｍＩＵ／ｍｌ、６７．７ｍＩＵ／ｍｌ。

The protective efficacy and immunogenicity of recombinant yeastderived hepatitis B vaccine, was observed in newborns whose mothers were both HBsAg and HBeAg positive, 52 infants were immunized with three doses of recombinant yeastderived hepatitis B vaccine (5μg/05ml) by 0,1,6 month schedule after birth The results showed that after three doses, At 3,9 and 12 months old, the protective rates of prevention of perinatal transmisson were 855%, 900% and 918%, seroconversion rates and antiHBs geometric mean titres were 830% and 376mIU/ml, 920% and 718%mIU/ml, 938% and 677mIU/ml respectively The results showed that the recombinant yeastderived hepatitis B vaccine was more effective than serum Hepatitis B vaccine